Vaccines & Biodefense

In the U.S., the recommended immunization series prevents approximately 33,000 deaths each year. Advancements in biotechnology have made it possible to produce vaccines that cannot transmit a virus or bacterium. This method has helped create more than 20 new vaccines against infectious agents, improved existing vaccines, and increased the amount of vaccine that can be produced.

Partnering with the Department of Defense to Protect the Warfighter: Investments in National Health Security

Webinar recorded on June 30, 2022, and moderated by Phyllis Arthur, Vice President, Infectious Disease and Emerging Science Policy, BIO. Webinar slides are available at this link.

The US Government invests in biomedical research in many ways, including direct funding of some critical R&D areas for diagnostics, vaccines, and therapeutics that could strengthen biodefense preparedness. This three-part webinar details for the biotechnology corporate and academic community the many new and previously available sources of capital, as well as the processes for applying for funding, from the US Department of Defense.

The Department of Defense (DoD) is continuously engaging in efforts to protect the warfighter from a broad array of threats. Preparing for and responding to these threats requires key partnerships with the industry to develop vaccines, therapeutics, and diagnostics that are designed specifically to meet the unique needs of the warfighter in various situations. Many of the investments made through these partnerships also support broader applications of key biotechnologies for other unmet healthcare needs. This important webinar represents an opportunity for BIO members and the whole biotechnology community to get an update about the priorities and programs within the DoD and the ways companies can work with the Agency on their priorities.

Part 1—Opening Remarks on DoD Priorities and Investing at the Speed of Need: Novel Technologies and Platforms to Accelerate Drug Development (60 minutes)

Part 2—Repurposing and Redirecting: An Alternate Approach to Accelerating Medical Countermeasures (42 minutes)

Part 3—How to Work with DoD (16 minutes)

Part 1 of 3—Investing at the Speed of Need: Novel Technologies and Platforms to Accelerate Drug Development

Part 2 of 3—Repurposing and Redirecting: An Alternate Approach to Accelerating Medical Countermeasures

Part 3 of 3—How to Work with DoD

Biotech Response to COVID-19

As the threat of the novel coronavirus continues to grow globally, innovative biopharmaceutical companies are ramping up efforts to study the virus and develop vaccines and cures to protect individuals from contracting the virus.

Learn More

Press Releases

BIO Commends FDA Plan to Establish a Rare Disease Innovation Hub to advance rare disease collaboration, treatments

July 17, 2024

July 17, 2024 – BIO President and CEO John F. Crowley today released the following statement after the U.S. Food & Drug Administration (FDA) announced a plan to establish a Rare Disease Innovation Hub that will utilize new and collaborative approaches to expedite the development and approval of…

BIO Applauds Introduction of Bipartisan Legislation to Reauthorize Program That Encourages Rare Pediatric Disease Research

June 20, 2024

BIO President and CEO John F. Crowley today released the following statement after a bipartisan group of Senators, Sen. Bob Casey (D-PA), Sen. Markwayne Mullin (R-OK), Sen. Sherrod Brown (D-OH), and Sen. Susan Collins (R-ME), introduced the Creating Hope Reauthorization Act to reauthorize the Rare…

BIO International Convention Celebrates Another Successful Year as Biotech Industry’s Largest and Most Influential Event

June 10, 2024

Biotechnology Innovation Organization (BIO) is proud to conclude the 2024 BIO International Convention in San Diego, held last week June 3-6, 2024. 1,400 exhibitors and more than 19,500 attendees from 70 countries came together for four full days of programming designed to propel the biotechnology…

Letters, Comments & Testimony

BIO Comments to the Minnesota Department of Health on Drugs of Substantial Public Interest: Draft Methodology for Public Comment

May 9, 2024

BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.

BIO Comments to HHS's Centers for Medicare & Medicaid Services in response to their Information Collection Request (ICR) on the Part C and Part D Medicare Prescription Payment Plan

April 19, 2024

The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.

BIO Statement to the Senate 340B Bipartisan Working Group on Safeguarding and Strengthening 340B

April 1, 2024

In response to the 340B Request for Information issued by the Senate 340B Bipartisan Working Group, BIO submits detailed comments.

Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.

Join BIOAction